Recent Updates — MDXH
MDxHealth SA is seeking shareholder approval at an extraordinary general meeting on November 19, 2026, for a share consolidation (reverse stock split) with a ratio between 1-for-5 and 1-for-30. The board will determine the final ratio within this range and implement the split within six months of approval. This action aims to address Nasdaq listing compliance requirements by increasing the per-share price. MDxHealth SA develops and markets non-invasive diagnostic tests for colorectal cancer.
MDxHealth announced preliminary third-quarter 2026 revenue from continuing operations of approximately $22.7 million, matching the prior-year period. The company suspended its full-year 2026 revenue guidance of $110–115 million due to unexpected sales force turnover and aggressive recruiting by competitors following the discontinuation of Resolve mdx. Third-quarter tissue-based test volume decreased 11% to 11,232, while liquid-based Exo mdx volume rose to 11,792 from 4,600 in the prior year. Cash and cash equivalents stood at $31.7 million as of September 30, 2026. MDxHealth is a precision diagnostics company providing molecular tests for prostate cancer and urologic diseases.
MDxHealth SA reported a net loss of $20.4 million and revenue of $51.1 million for the six months ended June 30, 2026. The company discontinued its Resolve UTI testing business and closed its Plano, Texas laboratory in May 2026, classifying it as a discontinued operation with a net loss of $1.2 million. On August 13, 2026, MDxHealth completed a registered direct placement of 44,052,862 ordinary shares at $0.454 per share, raising $20 million in gross proceeds to address liquidity concerns. The company remains in non-compliance with Nasdaq's minimum bid price requirement, facing a compliance deadline of December 28, 2026. MDxHealth operates in the precision diagnostics industry, developing and commercializing genomic testing solutions for prostate cancer.
MDxHealth SA issued and sold 44,052,862 ordinary shares in a registered direct offering at $0.454 per share to institutional investors on August 13, 2026. The transaction generated approximately $20.0 million in net proceeds before expenses, which the company intends to use for working capital, product development, and commercialization expansion. Post-offering, total outstanding shares increased to 95,417,382. MDxHealth SA operates in the healthcare diagnostics industry, developing non-invasive tests for colorectal cancer screening.
MDxHealth SA reported second quarter 2026 revenue of $27.2 million, a 16% increase year-over-year and a $3.3 million sequential rise from Q1. The company maintained its full-year 2026 revenue guidance of $110-115 million. Operating loss widened to $5.1 million due to expenses from the ExoDx acquisition, resulting in a net loss of $9.5 million and negative adjusted EBITDA of $(2.3) million. Concurrently, MDxHealth executed a registered direct placement of 44,052,862 ordinary shares at $0.454 per share, raising $20 million in gross proceeds to strengthen its balance sheet. The firm also finalized the wind-down of its discontinued Resolve mdx business through an Assignment for the Benefit of Creditors. MDxHealth SA operates in the precision diagnostics industry, providing molecular tests for prostate cancer and urologic diseases.
Mdxhealth SA received a notification from Nasdaq stating that its Market Value of Listed Securities was below the $35 million minimum requirement for the period from June 1, 2026, to July 17, 2026. The company has a 180-day compliance period ending January 19, 2027, to regain compliance. Mdxhealth is a urology-focused precision diagnostics company providing molecular information for prostate cancer diagnosis and treatment.